ARA Aura Renewable Acquisitions Plc

RNS Number:6375N
Ardana PLC
16 June 2005

                          ARDANA SIGNS AGREEMENT WITH
                  CYTOCHEMIA TO MARKET STRIANT(TM) SR IN GERMANY

Edinburgh, UK, 16 June 2005;  Ardana plc (LSE:ARA) the emerging pharmaceutical
company focused on improving human reproductive health, today announces that it
has signed an agreement under which Ardana grants Cytochemia AG exclusive rights
to market Striant(TM) SR in Germany.

Striant(TM) SR is a mucoadhesive buccal (gum surface) testosterone replacement
therapy for primary and secondary male hypogonadism (i.e. those suffering from a
deficiency or absence of testosterone). Striant(TM) SR is the first-to-market
buccal adhesive tablet and is marketed by Ardana's own sales force in the UK, to
urologists and endocrinologists. Cytochemia has considerable experience in
Germany selling to the same specialists through their targeted sales force which
has a strong track record in the education of physicians on product usage.
Cytochemia has a strong complementary portfolio to Ardana and its product
ImmuCyst, which has been on the market for 13 years, is an established agent for
the treatment and prevention of superficial bladder cancer. Striant(TM) SR
presents an excellent strategic fit with Cytochemia's product portfolio and will
be an important addition.

Cytochemia expects to launch Striant(TM) SR in the German market later this year.
Financial terms were not disclosed but Ardana will receive an upfront payment
and ongoing revenues for the supply of Striant(TM)SR to Cytochemia.

Dr. Maureen Lindsay, Chief Executive of Ardana, said: "As the biggest and most
developed market in Europe for testosterone replacement, Germany is key for
Striant(TM) SR.  In partnering with Cytochemia we believe that the product is in
the best hands to ensure a successful introduction there.  Striant's novel and
efficient delivery of testosterone has received high levels of acceptance from
both patients and prescribers."

For more information contact:
Ardana                                  Financial Dynamics
Maureen Lindsay                         (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550              Julia Phillips/Davina Langdale
                                        Tel: +44 (0)20 7831 3113

                                        NB Public Relations
                                        (trade/technical media relations)
                                        Nicki Brimicombe
                                        Tel: + 44 (0)1883 732353


About Ardana
Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.  Since its foundation, Ardana has maintained a broad and
balanced portfolio to manage risk and actively pursues product and technology
in-licensing and out-licensing to maintain a robust pipeline.

Ardana's four lead products are summarised below:

  * Striant(TM) SR, a testosterone replacement therapy that has already been
    launched by Ardana through its own sales force in the UK as a treatment for
    men with hypogonadism and for which Ardana has marketing rights in Europe;
  * Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  * Testo Bi-gel, a trans dermal testosterone delivery system in development
    for the treatment of male hypogonadism, shortly to enter Phase II trials;
  * Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.

In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana completed its IPO on the London Stock Exchange in March 2005 raising #21
million.

For further information please see www.ardana.co.uk

Cytochemia
Cytochemia is an independent pharmaceutical company based in Germany
specializing in immuno-therapeutics from either their own product development or
exclusive licence agreements. The target group for Cytochemia's therapeutics
consists of gynaecologists, oncologists and urologists. The company is primarily
active in the German market but in 2000 the company founded another branch of
the business in Switzerland.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRPKAKDKBKKKAD

Aura Renewable Acquisiti... (LSE:ARA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024

Aura Renewable Acquisiti... (LSE:ARA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024